Curient Announces Final Phase 1 Results of Adricetinib at AACR

RP2D and Excellent Safety Profile Demonstrated
Smooth Progress in Hematologic Cancer Indication Development...
"Thanks to Successful Phase 1 Results"

Curient, an innovative new drug developer, announced on April 29 that it presented the final results of the Phase 1 clinical trial of Adricetinib (Q702) for solid tumors at the American Association for Cancer Research (AACR 2025).

In addition to the dose escalation results from the Phase 1 clinical trial, which were disclosed at the Society for Immunotherapy of Cancer (SITC) in November 2023, the company released final results reflecting data from a total of 51 patients, including 11 additional patients in the dose expansion phase.

Through the clinical trial, Curient determined the recommended Phase 2 dose (RP2D), and confirmed not only a sufficient level of safety, but also significant changes in pharmacokinetic and pharmacodynamic (PK/PD) markers. Based on the successful Phase 1 results, Adricetinib is being developed for hematologic cancer indications in collaboration with leading medical institutions worldwide.

The ongoing acute myeloid leukemia clinical trial with MD Anderson Cancer Center is developing a triple combination therapy with azacitidine and venetoclax as a first-line treatment. The rare hematologic cancer clinical trial with Mayo Clinic is expected to achieve rapid regulatory approval, as clinical development is possible with a small number of patients.

Chronic graft-versus-host disease (cGvHD) is a major complication that occurs after allogeneic hematopoietic stem cell transplantation in patients with hematologic cancers. Adricetinib is expected not only to have a therapeutic effect on cGvHD, but also to suppress minimal residual disease (MRD).

Nam Kiyeon, CEO of Curient, said, "The reason Adricetinib was able to expand its indications through collaboration with world-class researchers was thanks to the successful Phase 1 results that demonstrated its safety," adding, "We are conducting clinical trials starting with hematologic cancer indications where the path to approval is clear, so we expect stable development going forward."